Many moving parts here. What could go right, and if it did what would happen? All based on the belief A2-73 will continue to perform.
I agree, some will show big changes and medicine will begin to understand how much it currently does not know. Predict many AHAAH moments to follow.
You have presented a fair read of the situation.Bio is notorious for surprises, which makes some of us nervous....including me, although I anticipate good news.
If FDA is informed or has staying in touch as collaborative plan with AVXL anything is possible. May explain emphasis on safety. Cognitive skills progress/changes are basis for pass/fail in trial as I understand it. Keeping this as simple a process as possible would be great.
I agree...can anyone untangle this note from AAIC ..in context?
"Note: AAIC 2016 Developing Topic abstracts will be considered for poster presentation only unless the research is considered to be late-breaking. "
"Developing Topic Abstract Submissions
All abstract submissions have closed for AAIC 2016. Sign up for email updates to be notified when submissions open for AAIC 2017.
Developing Topic submissions are designed to bring the latest research findings in the field to AAIC attendees. Specifically, Developing Topic abstracts present research findings that were not available at the time of the general abstract submission deadline in February.
Note: AAIC 2016 Developing Topic abstracts will be considered for poster presentation only unless the research is considered to be late-breaking.
Massive, brilliant, if these claims are demonstrated....A2-73 presents a new beginning for medicine. BTD will not get any bigger.. Great information, thanks.
If AAIC has a rule on # days prior to event for late breaking PR then we are not there yet. As has been posted, the company says they will send PR prior to event, all good.
"NEW YORK, NY – June 30, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the presentation of initial clinical data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 during the upcoming Alzheimer’s Association International Conference® 2015 (AAIC), which takes place in Washington D.C. from July 18-23, 2015."
Done about 3 weeks before event and I can find no evidence from any other firm of any AAIC PR for late breaking for AAIC 2016 so far. Keep looking. Keep calm, return fire.
I am expecting an additional PR from Anavex. I do expect a podium presentation in addition to posters. Reported by another person earlier said company will issue PR prior to session. Reviewed last years PR and see it was about 3 weeks prior to session. Have not seen ANY other late breaking news from AAIC yet.
An individual may be the presenting author on one podium presentation at AAIC.
Podium presentations include featured research, oral, symposium and plenary sessions.
Podium presentation in a preconference does not count towards AAIC.
Exception: An individual may only present in two AAIC podium platforms if one is a
Developing Topic session (i.e. late breaking abstracts collected in the spring)."
squal...are you certain? Can you provide any AAIC doc/text that says it is 1 hr developing topic presentation? It should one or the other??